ИССЛЕДОВАНИЕ АНТИГЕН-СТИМУЛИРОВАННОЙ ПРОДУКЦИИ υ-ИНТЕРФЕРОНА EX VIVO В ПЕРИФЕРИЧЕСКОЙ КРОВИ У БОЛЬНЫХ АКТИВНЫМ ТУБЕРКУЛЕЗОМ ЛЕГКИХ

Tuberculosis (TB) is one of the most significant problems in the Russian Health Care. Russia remains on the list of the 22 countries with a high TB incidence and on the third place in the world with a high prevalence of Drug Resistant TB [1]. It is urgently needed to develop new TB diagnostic methods as well as effective measures of the specific TB prevention, including a development of the novel vaccines, so we have to know better about the most immunogenic antigens of Mycobacterium Tuberculosis. We studied the Interferon-Q production in the whole blood after stimulating immune response with different proteins of Mycobacterium Tuberculosis in patients with active TB. The study results permitted us to evaluate the immunogenicity of the previously known proteins (Ag85a и ESAT-6) in comparison to the recently identified ones (Rv2957, Rv2958c и Rv0447), analyzing simultaneously their relation to tuberculin, as well as to antigens of the different viruses (Human Immunodeficiency Virus, Cytomegalovirus, Epstein-Barr Virus, Influenza Virus). Protein Rv2958c, unlike protein ESAT-6, showed the high immunogenicity in comparison to tuberculin. The expressed immunogenicity of protein Rv2958c might be indicated a possible greatest specificity of immune response to this antigen in TB patients. Meanwhile, bacillary tuberculosis was strongly associated with low immune response to this protein. Also we were found statistical differences in immune responses of patients to the different Mycobacterium Tuberculosis antigens depending on the drug sensitivity. In addition it was interesting to know about a significantly low immune response of patients with Drug Resistant TB to protein pp65 CMV.Туберкулез является одной из наиболее серьезных проблем российского здравоохранения. Россия остается в списке из 22 стран с высокой заболеваемостью туберкулезом и на 3-м месте в мире по распространенности лекарственно-устойчивых форм заболевания. Требуется разработка как новых методов диагностики, так и эффективных мер специфической профилактики, включая новые вакцины, для создания которых необходимо знание наиболее иммуногенных антигенов Mycobacterium tuberculosis. В данной работе исследовалась продукция интерферона-гамма в цельной крови пациентов с активным туберкулезом в ответ на антиген-стимуляцию различными белками Mycobacterium tuberculosis. Результаты исследования позволили дать оценку иммуногенности ранее изученных белков (Ag85a и ESAT -6) в сравнении с недавно идентифицированными белками (Rv 2957, Rv 2958c и Rv0447) с одновременным изучением их отношений к туберкулину и антигенам различных вирусов (вирус иммунодефицита человека, цитомегаловирус, вирус Эпштейна – Барр, вирус гриппа). Белок Rv2958c, в отличие от белка ESAT T-6, показал большую иммуногенность при сравнении с туберкуэффективлином. Выраженная иммуногенность белка Rv2958c может свидетельствовать о возможно большей специфичности иммунного ответа на этот антиген у больных туберкулезом. Между тем бактериовыделение было ассоциировано с достоверно низким иммунным ответом на данный белок. Также выявлены статистические различия в иммунореактивности пациентов к различным антигенам Mycobacterium tuberculosis в зависимости от наличия или отсутствия лекарственной устойчивости возбудителя. Представляет интерес достоверно низкая иммунореактивность пациентов с лекарственно-устойчивым туберкулезом в отношении белка pp65 CMV

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Supported by F. Hoffmann–La Roche

Antigen induced production of υ-interferon ex vivo, in the peripheral blood of patients with active pulmonary tuberculosis

Tuberculosis (TB) is one of the most significant problems in the Russian Health Care. Russia remains on the list of the 22 countries with a high TB incidence and on the third place in the world with a high prevalence of Drug Resistant TB [1]. It is urgently needed to develop new TB diagnostic methods as well as effective measures of the specific TB prevention, including a development of the novel vaccines, so we have to know better about the most immunogenic antigens of Mycobacterium Tuberculosis. We studied the Interferon-Q production in the whole blood after stimulating immune response with different proteins of Mycobacterium Tuberculosis in patients with active TB. The study results permitted us to evaluate the immunogenicity of the previously known proteins (Ag85a и ESAT-6) in comparison to the recently identified ones (Rv2957, Rv2958c и Rv0447), analyzing simultaneously their relation to tuberculin, as well as to antigens of the different viruses (Human Immunodeficiency Virus, Cytomegalovirus, Epstein-Barr Virus, Influenza Virus). Protein Rv2958c, unlike protein ESAT-6, showed the high immunogenicity in comparison to tuberculin. The expressed immunogenicity of protein Rv2958c might be indicated a possible greatest specificity of immune response to this antigen in TB patients. Meanwhile, bacillary tuberculosis was strongly associated with low immune response to this protein. Also we were found statistical differences in immune responses of patients to the different Mycobacterium Tuberculosis antigens depending on the drug sensitivity. In addition it was interesting to know about a significantly low immune response of patients with Drug Resistant TB to protein pp65 CMV

IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function

Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency associated with an increased susceptibility to herpesvirus infection and hematologic malignancy as well as a deficiency of NK cell function. It is caused by defective WAS protein (WASp). WASp facilitates filamentous actin (F-actin) branching and is required for F-actin accumulation at the NK cell immunological synapse and NK cell cytotoxicity ex vivo. Importantly, the function of WASp-deficient NK cells can be restored in vitro after exposure to IL-2, but the mechanisms underlying this remain unknown. Using a WASp inhibitor as well as cells from patients with WAS, we have defined a direct effect of IL-2 signaling upon F-actin that is independent of WASp function. We found that IL-2 treatment of a patient with WAS enhanced the cytotoxicity of their NK cells and the F-actin content at the immunological synapses formed by their NK cells. IL-2 stimulation of NK cells in vitro activated the WASp homolog WAVE2, which was required for inducing WASp-independent NK cell function, but not for baseline activity. Thus, WAVE2 and WASp define parallel pathways to F-actin reorganization and function in human NK cells; although WAVE2 was not required for NK cell innate function, it was accessible through adaptive immunity via IL-2. These results demonstrate how overlapping cytoskeletal activities can utilize immunologically distinct pathways to achieve synonymous immune function